BXQ-350 is under clinical development by Bexion Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect BXQ-350’s likelihood of approval (LoA) and phase transition for Glioblastoma Multiforme (GBM) took place on 26 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 26 Dec 2022 increased BXQ-350’s LoA and PTSR for Recurrent Glioblastoma Multiforme (GBM).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BXQ-350 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

BXQ-350 overview

BXQ-350 is under development for the treatment of cancers including glioblastoma, lung squamous cell carcinoma, malignant glioma, pancreatic cancer, prostate cancer, ependymoma, pediatric diffuse intrinsic pontine glioma, diffuse midline glioma (DMG) and other solid tumors and unspecified central nervous system disorders, lysosomal storage disorder and unspecified viral infections. The drug candidate is administered through intravenous injection. The drug candidate is developed based on Dubbed SapC-DOPS technology. BXQ-350 is a nanovesicle formulation of synthetically produced, human lysosomal protein saposin C (sphingolipid activator protein, or SapC, 80 aa) and the phospholipid dioleoylphosphatidylserine (DOPS). BXQ-350 targets phosphatidylserine (PS) lipids.

It was also under development for the treatment of malignant peripheral nerve sheath tumor, head and neck cancer, neuroblastoma, recurrent solid tumors, brain tumor, breast cancer, pineoblasotoma, osteosarcoma.

Bexion Pharmaceuticals overview

Bexion Pharmaceuticals is a healthcare products and services provider that develops therapies. The company primarily focused in discovery and clinical development of life-changing oncology treatments. The company develops and commercializes drugs for the treatment of cancer. Bexion Pharmaceuticals phospholipid dioleoylphosphatidylserine is used for targeting and treating cancers such as glioblastoma multiforme. The company’s BXQ-350 is a formulation of a synthetically produced human lysosomal protein. It operates through cancer institute for the research on BXQ-350 nanovesicle for the treatment of cancer. Bexion Pharmaceuticals is headquartered in Covington, Kentucky, the US.

Quick View BXQ-350 LOA Data

Report Segments
  • Innovator
Drug Name
  • BXQ-350
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Genetic Disorders
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
  • Toxicology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.